- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06194877
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 With Panitumumab in Patients With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
The primary objectives of Part 1 of this study are to:
- Assess the safety and tolerability of the combination of BGB-3245 and panitumumab in participants with advanced or metastatic colorectal cancer (CRC) with a known mutation status and tumor harboring an oncogenic mutation of v-Raf murine sarcoma viral oncogene homolog B; B-RAF proto-oncogene, serine/threonine kinase (BRAF), Kirsten rat sarcoma viral oncogene homolog (KRAS), or neuroblastoma RAS viral oncogene homolog (NRAS) with documented disease progression during or after at least 1 line of prior therapy.
- Determine the maximum tolerated dose (MTD) of BGB-3245 in combination with panitumumab and the recommended phase 2 dose (RP2D) of the combination.
The primary objective of Part 2 of this study is to determine the objective response rate (ORR) as assessed by initial investigator review using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 with BGB-3245 and panitumumab combination treatment at the RP2D.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: MapKure
- Phone Number: 1-877-828-5568
- Email: clinicaltrials@mapkure.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Comprehensive Cancer Center - Duarte
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- USOR - Virginia Cancer Specialists - Fairfax Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participants with histologically confirmed advanced or metastatic solid tumors who have had documented disease progression by RECIST criteria during or after at least 1 prior line of systemic anticancer therapies in the representative population or are unable to receive standard of care therapy(ies) as noted by local guidelines.
- Part 1 (Dose Finding): Participants with CRC with a known mutation status by local testing and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS in the archival tumor sample or fresh tumor biopsy.
- Part 2 (Dose Expansion): Participants must have a known mutation status by local testing and meet one of the following criteria according to the group they are enrolled into: Group 1: Participants with CRC that harbors KRAS or NRAS mutations in the archival tumor sample or fresh tumor biopsy. Group 2: Participants with PDAC that harbors KRAS mutations in the archival tumor sample or fresh tumor biopsy.
- Participants must provide archival tumor tissue or a fresh tumor biopsy for retrospective mutation status analysis.
- Participants must have radiologically measurable disease as defined per RECIST v1.1 at screening.
- Eastern Cooperative Oncology Group performance status of ≤1 at screening.
- Adequate hematologic and organ function, as indicated by defined laboratory values, prior to Cycle 1 Day 1.
- Adequate cardiac function.
Key Exclusion Criteria:
- Participants receiving cancer therapy (chemotherapy or other systemic anticancer therapies, immunotherapy, radiation therapy, or surgery) at the time of Cycle 1 Day 1.
- Active infection requiring systemic treatment at the start of the study treatment.
- Clinically significant cardiovascular disease and / or events within 6 months of signing the informed consent form.
- Participants with toxicities that have not recovered to Grade ≤1 or stabilized and those Grade 2 toxicities listed as permitted in other eligibility criteria.
- Participants with a history of pneumonitis or interstitial lung disease.
- Participants with immune-related toxicities that have not resolved with appropriate management.
- History or presence of gastrointestinal disease or other condition known to interfere with the absorption of drugs.
- History of ulcerative colitis or Crohn's disease or protracted and ongoing immune-mediated diarrhea from prior checkpoint inhibitor use.
- History of corneal perforation, keratitis, or severe dry eye.
- Current evidence of symptomatic central nervous system metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression.
- Any active malignancy ≤3 years before Cycle 1 Day 1 except for the specific cancer under investigation in this study and any localized or noninvasive cancer that has been treated curatively.
- Known hypersensitivity to rapidly accelerated fibrosarcoma (RAF) inhibitors, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or their excipients.
- Any known history of Grade ≥3 toxicity lasting >14 days from another RAF, mitogen activated protein kinase, extracellular signal-regulated kinase, or anti-EGFR antibody inhibitor requiring discontinuation of treatment from these drugs.
- Receiving any treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor or inducer ≤14 days (or 5 half-lives, whichever is longer) before Cycle 1 Day 1 and until completion of dosing with BGB-3245 for at least 5 half-lives.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply. Summary of key criteria provided.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Dose Finding Part
Participants with advanced or metastatic CRC and with known mutation status and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS and with documented disease progression by RECIST during or after at least 1 line of prior therapy will be enrolled into 4 planned sequentially run cohorts.
Participants will receive escalating doses of BGB-3245 in combination with panitumumab to establish the MTD and RP2D by assessing the safety, tolerability, preliminary antitumor activity, and pharmacokinetics (PK) for the combination of BGB-3245 with panitumumab.
|
Oral capsule
Other Names:
Intravenous (IV) infusion via an infusion pump
Other Names:
|
Experimental: Part 2: Dose Expansion Part, Group 1
Participants with advanced or metastatic CRC that harbors KRAS or NRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy.
Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
|
Oral capsule
Other Names:
Intravenous (IV) infusion via an infusion pump
Other Names:
|
Experimental: Part 2: Dose Expansion Part, Group 2
Participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that harbors KRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy.
Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
|
Oral capsule
Other Names:
Intravenous (IV) infusion via an infusion pump
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1: Number of Participants with Serious Adverse Events (SAEs)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1: Number of Participants with Adverse Events of Special Interest (AESIs)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1: Number of Participants with Interruptions to Dosing with BGB-3245
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1: Number of Participants with Reductions in Dosing with BGB-3245
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1: MTD of BGB-3245
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1: RP2D of BGB-3245
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: ORR as Assessed by Initial Investigator Review
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1 and 2: Plasma Concentrations of BGB-3245 and Any Relevant Metabolites
Time Frame: Day 1 of each 28 day cycle (up to approximately 2 years)
|
Day 1 of each 28 day cycle (up to approximately 2 years)
|
Part 1: ORR as Assessed by Investigator Review using RECIST v1.1
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: ORR as Assessed by Central Review
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1 and 2: Duration of Response (DoR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1 and 2: Disease Control Rate (DCR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 1 and 2: Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: Number of Participants with SAEs
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: Number of Participants with TEAEs
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: Number of Participants with AESIs
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: Number of Participants with Interruptions to Dosing with BGB-3245
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Part 2: Number of Participants with Reductions in Dosing with BGB-3245
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BGB-3245-EGFR-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on BGB-3245
-
MapKure, LLCRecruitingSolid Tumor | B-Raf Mutation-Related TumorsUnited States, Australia
-
SpringWorks Therapeutics, Inc.Recruiting
-
BeiGeneCompleted
-
BeiGeneTerminatedAdvanced Solid TumorsAustralia, Spain, New Zealand
-
BeiGeneRecruitingRefractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditionsChina, Australia
-
BeiGeneCompletedFor Participants With Advanced Solid Tumors Failed With Previous Lines of TreatmentAustralia
-
BeiGeneCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); BerGenBio ASATerminatedBrain and Central Nervous System TumorsUnited States
-
BeiGeneCompletedSolid TumorsAustralia, New Zealand
-
Fudan UniversityRecruitingLimited Stage Small Cell Lung CancerChina